



## **Jazz Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference on November 12**

November 1, 2013

DUBLIN, Nov. 1, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 2013 Credit Suisse Healthcare Conference in Phoenix, AZ.

Bruce C. Cozadd, chairman and chief executive officer, will provide an overview of the company at the conference on Tuesday, November 12, at 11:30 a.m. MST / 6:30 p.m. GMT.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com). Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).

### **About Jazz Pharmaceuticals**

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem<sup>®</sup> (sodium oxybate) oral solution, Erwinaze<sup>®</sup> (asparaginase *Erwinia chrysanthemi*), Prialt<sup>®</sup> (ziconotide) intrathecal infusion, FazaClo<sup>®</sup> (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).

SOURCE Jazz Pharmaceuticals plc

Kathee Littrell, Vice President, Investor Relations, Jazz Pharmaceuticals plc, Ireland, + 353 1 634 7887, U.S., + 1 650 496 2717